Background & Aims: Direct comparisons of bismuth and proton pump inhibitor (PPI)-based
triple and quadruple therapies for Helicobacter pylori eradication are lacking. To address …

Eradication therapy has been incorporated into clinical practice. The regimens currently
recommended for first-line treatment include a 2-week bismuth-based triple therapy (mainly …

Aim: To evaluate Helicobacter pylori primary resistance and its clinical impact on the efficacy
of two lansoprazole‐based eradication triple therapies. Methods: H. pylori‐positive patients …

Aim: To test the efficacy of omeprazole, furazolidone and amoxicillin triple therapy for the
treatment of Helicobacter pylori infection after failure of standard first‐line therapy …

Of 96 Helicobacter pylori isolates from patients in Shanghai and Guangzhou, China, 5 had
the A2143G 23S rRNA mutation as determined by primer-mismatch PCR and were resistant …

Abstract Background. Clarithromycin‐resistant Helicobacter pylori (CRHP) is increasing
worldwide. Clarithromycin resistance in H. pylori from familial members has not been …

Background: Numerous serological tests for the detection of Helicobacter pylori infection
have been developed. However, many perform poorly when evaluated in the Chinese …

Background: We have previously shown that ranitidine bismuth citrate‐based, clarithromycin‐
containing triple therapy achieves a higher eradication rate than proton pump inhibitor …

Clinical scientists from eight European countries and China gathered in the ancient Chinese
capital of Xi'an on April 26-28, 2001 to discuss collaboration on a modern approach to …

In conclusion, the prevalence of metronidazoleand clarithromycin-resistant H. pylori strains
increased. In addition, dual resistance to clarithromycin and metronidazole H. pylori strains …